Q3 2025 Novo Nordisk A/S Earnings Call Transcript

Nov 5, 2025 / 12:00 PM GMT

Release Date Price: $48.46 (+0.44%)

Transcript

Key Points

Positve

Novo Nordisk AS (NVO) reported a 15% increase in sales and a 10% rise in operating profit for the first nine months of 2025.
The company has expanded its reach, now serving around 46 million people with diabetes and obesity, an increase of 3 million from the previous year.
Novo Nordisk AS (NVO) is intensifying its focus on core areas such as diabetes and obesity, which is expected to drive future growth.
The company is undergoing a transformation to simplify its operating model, which is expected to save approximately DKK 8 billion annually by the end of 2026.
Novo Nordisk AS (NVO) is actively pursuing strategic acquisitions, such as the proposed acquisition of Metsera, to enhance its R&D portfolio and address unmet medical needs.

Negative

Novo Nordisk AS (NVO) has narrowed its sales growth guidance to 8-11% and operating profit growth to 4-7%, citing lower growth expectations for GLP-1 treatments in diabetes and obesity.
The company is facing intensifying competition in both diabetes and obesity markets, which is impacting its market share.
Novo Nordisk AS (NVO) plans to reduce approximately 9,000 positions globally as part of its transformation program, which could have a significant human impact.
The company is experiencing pricing pressure and competition in the US market, particularly affecting its GLP-1 diabetes care products.
Novo Nordisk AS (NVO) is dealing with challenges related to compounded GLP-1 products in the US, which are impacting its market dynamics.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

NOVOb.CO - Novo Nordisk A/S
Q3 2025 Novo Nordisk A/S Earnings Call
Nov 05, 2025 / 12:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Good day and thank you for standing by. Welcome to the Q3 2025 Novo Nordisk earnings conference call.

At this time, all

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.